Circularly permuted TRAIL - Beijing Sunbio Biotech

Drug Profile

Circularly permuted TRAIL - Beijing Sunbio Biotech

Alternative Names: CPT - Beijing Sunbio Biotech; Human recombinant Apo2L/TRAIL; Human recombinant circularly permuted TRAIL - Beijing Sunbio Biotech; Human recombinant CPT - Beijing Sunbio Biotech; Recombinant Apo2L - Beijing Sunbio Biotech; Recombinant TRAIL

Latest Information Update: 08 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Beijing Sunbio Biotech
  • Developer Beijing Chao-Yang Hospital; Beijing Sunbio Biotech; Fudan University Shanghai Cancer Center
  • Class Antineoplastics; Recombinant proteins
  • Mechanism of Action Apoptosis stimulants; TRAIL receptor 1 agonists; TRAIL receptor 2 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Multiple myeloma; Solid tumours

Most Recent Events

  • 07 Sep 2017 Discontinued - Phase-II for Multiple myeloma (Combination therapy, Second-line therapy or greater) in China (IV)
  • 07 Sep 2017 Discontinued - Phase-II for Multiple myeloma (Second-line therapy or greater) in China (IV)
  • 07 Sep 2017 Discontinued - Phase-II for Solid tumours (Second-line therapy or greater) in China (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top